AbstractIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterized by the development of subpleural foci of myofibroblasts that contribute to the exuberant fibrosis. Recent studies revealed that pleural mesothelial cells (PMCs) undergo epithelial–mesenchymal transition (EMT) and play a pivotal role in IPF. In animal model, bleomycin induces pulmonary fibrosis exhibiting subpleural fibrosis similar to what is seen in human IPF. It is not known yet whether bleomycin induces EMT in PMCs. In the present study, PMCs were cultured and treated with bleomycin. The protein levels of collagen-I, mesenchymal phenotypic markers (vimentin and α-smooth muscle actin), and epithelial phenotypic markers (cytokeratin-8 and E-cadh...
Bleomycin (BLM) is a drug used to treat different types of neoplasms. BLM’s most severe adverse effe...
Chronic hypersensitivity pneumonitis (HP) causes progressive and irreversible pulmonary fibrosis, a ...
The origin of the myofibroblast in fibrotic lung disease is uncertain, and no effective medical ther...
AbstractIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterized by t...
IF 10.569International audienceIntroduction: In patients, the therapeutic use of bleomycin (BLM), a ...
IF 2.824International audienceThe clinical use of bleomycin is restrained because of its lung toxici...
Background: Idiopathic and toxic pulmonary fibrosis are severe diseases starting classically in the ...
Pulmonary fibrosis is a severe disease that contributes to the morbidity and mortality of a number o...
Abstract Background Epithelial to mesenchymal transition (EMT) in alveolar epithelial cells (AECs) h...
Abstract Background Pulmonary fibrosis is a progressive and lethal disease characterized by damage t...
Fibrosis and structural remodeling of the lung tissue can significantly impair lung function, often ...
The hypothesis that epithelial-mesenchymal transition (EMT) contributes to the formation of fibrobla...
The contribution of epithelial-to-mesenchymal transition (EMT) to the profibrotic stiff microenviron...
Idiopathic pulmonary fibrosis (IPF) is the prototypic progressive fibrotic interstitial lung disease...
2004.—Administration of bleomycin (BM) produces inflammation and fibrosis of the lung in humans and ...
Bleomycin (BLM) is a drug used to treat different types of neoplasms. BLM’s most severe adverse effe...
Chronic hypersensitivity pneumonitis (HP) causes progressive and irreversible pulmonary fibrosis, a ...
The origin of the myofibroblast in fibrotic lung disease is uncertain, and no effective medical ther...
AbstractIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterized by t...
IF 10.569International audienceIntroduction: In patients, the therapeutic use of bleomycin (BLM), a ...
IF 2.824International audienceThe clinical use of bleomycin is restrained because of its lung toxici...
Background: Idiopathic and toxic pulmonary fibrosis are severe diseases starting classically in the ...
Pulmonary fibrosis is a severe disease that contributes to the morbidity and mortality of a number o...
Abstract Background Epithelial to mesenchymal transition (EMT) in alveolar epithelial cells (AECs) h...
Abstract Background Pulmonary fibrosis is a progressive and lethal disease characterized by damage t...
Fibrosis and structural remodeling of the lung tissue can significantly impair lung function, often ...
The hypothesis that epithelial-mesenchymal transition (EMT) contributes to the formation of fibrobla...
The contribution of epithelial-to-mesenchymal transition (EMT) to the profibrotic stiff microenviron...
Idiopathic pulmonary fibrosis (IPF) is the prototypic progressive fibrotic interstitial lung disease...
2004.—Administration of bleomycin (BM) produces inflammation and fibrosis of the lung in humans and ...
Bleomycin (BLM) is a drug used to treat different types of neoplasms. BLM’s most severe adverse effe...
Chronic hypersensitivity pneumonitis (HP) causes progressive and irreversible pulmonary fibrosis, a ...
The origin of the myofibroblast in fibrotic lung disease is uncertain, and no effective medical ther...